Partners: Corporations

Wyeth Pharmaceuticals

 

rule

Study of Blood Inhibitors in Hemophilia Patients

To monitor hemophilia patients for the development of inhibitors and establish a surveillance system to collect and analyze a uniform set of clinical data.

  • Funding Partners: Wyeth Pharmaceuticals
  • Program Partners: Multiple hemophilia treatment centers; National Center on Birth Defects and Developmental Disabilities, CDC
Related Information: